Bmcgoo
Posted - 29 minutes ago
$AGEN Lookin' good. RSI looks great. RSI has been a good indicator.
Capitulation_0
Posted - 29 minutes ago
$AGEN point 72 is deep in this... Type B meeting with FDA. Should be in the 30's if you factor in RS
Zenlama
Posted - 1 hour ago
$AGEN Wait for it
StockTech7
Posted - 3 hours ago
$AGEN what's Garo's plan now. Does he think the stock price is actually going to go up on data and BLA so he can squeeze more money out of shareholders again or is some partner waiting for the BLA to come in and save the day. Wouldn't be surprised if he screws it up for shareholders again. 😬
manny11419
Posted - 17 hours ago
$AGEN I wonder if the high risk registration strategy cause Todd Yancey to leave..the shorts were correct on Bal/zal failure...it takes guts to short biotech stocks..and they've been right for the past few years. on the Nov. CC ...midyear BLA have been mentioned four times...sometimes. Sometimes the new guys don't want to be associated with optimistic languages..Gupta left in a hurry also.
docBNM
Posted - 17 hours ago
$AGEN Owner Name Date Shares Held Change (Shares) Change (%) Value (In 1,000s) Goldman Sachs Group Inc 3/31/2024 3,285,071 3,140,390 2170.561% $35,413
MoneyTalksStocksWalk
Posted - 22 hours ago
@OracleofOntario @Disney1295 I’m bullish on $AGEN as well, don’t get me wrong. But, I also know that a majority of investors and traders in the biotech world are abnormally impatient when it comes to biotech companies so majority of them exit then return at usually a cheaper position before the cascade of a catalyst occurs. I had many positions in AGEN and most recently sold at 13.03- I will re-enter in the $8-9$ range and wait - the probability of their BLA being accepted is probably 90% - considering most other treatments are entirely useless
Carl_K
Posted - 23 hours ago
$AGEN $INTS may be one to look into. "Data from that same trial presented at CTOS in November 2023 and ASCO 2023 in June 2023 showed a disease control rate of 93% for subjects on INT230-6 alone, and median overall survival of 21.5 months. Disease control rate measures the percentage of patients who have achieved stable disease, partial response or complete response.
In comparison, Agenus' (AGEN) combination therapy of immune-activating botensilimab and anti-PD-1 checkpoint inhibitor balstilimab, looked at as a very interesting drug candidate for a multitude of solid tumors, has a disease control rate of 63% in a Phase 1b trial, with a median of three prior lines of therapy. INT230-6's 93% disease control rate is well above that, for the same indication."
https://seekingalpha.com/article/4693038-intensity-therapeutics-a-bargain-for-a-late-stage-company-with-a-remarkable-oncology-drug
MITornado
Posted - 23 hours ago
$AGEN
OracleofOntario
Posted - 23 hours ago
$AGEN every time the company releases positive news the shorts pile on to keep the price from running - let's see how long they can keep that up.
docBNM
Posted - 1 day ago
$AGEN has there been any new fund/index purchases since the reverse split ? that's what it was for besides Naz listing !!!!
Gmanthemagnificent
Posted - 1 day ago
$AGEN this smells like the zal/ bal debacle all over again... stay tuned!
jacobsright
Posted - 1 day ago
$AGEN markets up , this pig is down again!
Scooter0732
Posted - 1 day ago
$AGEN Expected selloff on news that was known already to the market. I am happy to be invested here, and wait for when the company is ready to file a BLA because, quite simply, they are doing very important work. If you're in for the ride then this means nothing.
jacobsright
Posted - 1 day ago
$AGEN down 6% on positive news, cant wait until you get the bad news!
MITornado
Posted - 1 day ago
$AGEN $15 January 2024 options selling for $2.50. Selling here is ridiculous.
jacobsright
Posted - 1 day ago
$AGEN 52 cents a share pre split look out below!
weichsel1
Posted - 1 day ago
$AGEN Wacky. About 11.20 in pre-market trading. now 10.22. Down .56. All on good news from the FDA on approval process. Any explanation?
Disney1295
Posted - 1 day ago
$AGEN The other thing I should say is that I was a long suffering Red Sox fan. 1967, 1975, 1978, 1986, 2003 - were all brutal. That made 2004 all that much sweeter. It was the same as a Patriots fan. They were the laughing stock of the NFL in the 90’s including a 1-15 year. That too made 6 Super Bowl wins that much better. I absolutely believe AGEN will be similar. Unfortunately, it takes a lot of patience, but SO worth it.
Gmanthemagnificent
Posted - 1 day ago
$AGEN atm is back in play, the shorts know it! its going much lower folks!
Disney1295
Posted - 1 day ago
$AGEN This has to be one of the most frustrating stocks of all time.
StockConsultant
Posted - 1 day ago
$AGEN Agenus stock low volme pullback to 10.92 support area, high trade quality
jlemx
Posted - 1 day ago
$AGEN A lot of things are aligning. Agen is finally taking the desired course.
Moon37
Posted - 1 day ago
$AGEN
VvapWinner
Posted - 1 day ago
$AGEN This should go big by tomorrow
manny11419
Posted - 1 day ago
$AGEN Some 10K tidbits During the three months ended March 31, 2024, we received net proceeds of approximately $17.2 million from the sale of approximately 1.2 million shares of our common stock in at-the-market offerings under the Sales Agreement. In connection with the sale of the Purchased Assets, we issued to Ligand a warrant (“Warrant”) to purchase 867,052 shares of our common stock, at an exercise price equal to $17.30. The exercise price of the Warrant and the number of shares issuable upon exercise of the Warrant are subject to adjustments for stock splits, combinations, stock dividends or similar events. The Warrant is exercisable until May 6, 2029. Ligand got a very good deal if the stock goes back to $100 ($5 presplit) they'll make back the $75 mil.
DonCorleone77
Posted - 1 day ago
$AGEN FDA grants Agenus meeting to discuss BOT/BAL Therapy for r/r MSS mCRC Agenus announced it will conduct a Type B End-of-Phase 2 EOP2 meeting in July with the U.S. Food and Drug Administration or FDA, to discuss the botensilimab plus balstilimab BOT/BAL combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR r/r MSS mCRC , as well as the critical elements of the program to support a future biologics license application BLA submission. The FDA granted BOT/BAL fast track designation in April 2023. "Our upcoming End of Phase 2 meeting with the FDA represents a significant milestone in the ongoing development of BOT/BAL for patients diagnosed with metastatic MSS CRC who do not have active liver metastases," stated Steven O'Day, M.D., Chief Medical Officer of Agenus. "The results from our Phase 1 and Phase 2 studies contribute valuable insights into the potential of this therapy for managing a specific and challenging subgroup of colorectal cancer. We remain dedicated to further exploring innovative immunotherapeutic strategies." The Phase 2 data will be submitted to a major medical conference later this year. In addition to advancing BOT/BAL in colorectal cancer, Agenus remains committed to exploring the potential of this combination therapy in other cancer indications and is preparing to present further data at upcoming medical conferences.
Marinshell
Posted - 1 day ago
$AGEN here we go!
Aetas
Posted - 1 day ago
$AGEN finally some substance & facts that count
